Aristotle Capital Management, LLC, an investment management company, released its “Value Equity Strategy” second quarter 2025 investor letter. A copy of the letter can be downloaded here. Although the U.S. equity market started with volatility in the second quarter, it rebounded with strength, with the S&P 500 Index rising 10.94% during the quarter. The composite returned 4.88% gross of fees (4.75% net of fees) in the first quarter, outperforming the 3.78% return of the Russell 1000 Value Index and underperforming the 10.94% return of the S&P 500 Index. In addition, you can check the fund’s top 5 holdings to determine its best picks for 2025.
In its second quarter 2025 investor letter, Aristotle Capital Value Equity Strategy highlighted stocks such as Amgen Inc. (NASDAQ:AMGN). Amgen Inc. (NASDAQ:AMGN) is a biotech company that discovers, develops, manufactures, and delivers human therapeutics. The one-month return of Amgen Inc. (NASDAQ:AMGN) was 9.04%, and its shares lost 8.92% of their value over the last 52 weeks. On July 22, 2025, Amgen Inc. (NASDAQ:AMGN) stock closed at $305.69 per share, with a market capitalization of $164.371 billion.
Aristotle Capital Value Equity Strategy stated the following regarding Amgen Inc. (NASDAQ:AMGN) in its second quarter 2025 investor letter:
“Amgen Inc. (NASDAQ:AMGN), the biopharmaceutical company, was one of the largest detractors for the quarter. While the company’s branded drugs continued to advance (a previously identified catalyst), with cholesterol medicine Repatha, osteoporosis treatment Evenity and bone-strengthening drug Prolia all growing sales in the double digits, concerns surrounding potential tariff impacts, tax reform and pressure on drug prices weighed on shares. We believe it is too early to assess the full impact of these macro uncertainties and are confident in Amgen’s demonstrated ability to adapt through evolving policy and pricing dynamics. The company reaffirmed its long-term commitment to domestic manufacturing and innovation through its upcoming $2 billion expansions in Ohio and North Carolina, building on more than $5 billion in U.S. operational investments since 2017. Furthermore, Amgen continued to advance its robust pipeline, as its 1L bemarituzumab (bema) phase 3 trial for gastric cancer met its primary endpoint, and MariTide, the company’s weight-loss drug, demonstrated strong efficacy in phase 1 and 2 trials. MariTide, which could offer more convenient monthly dosing compared to daily or weekly regimens, showed promising early results, though tolerability will be an important focus heading into phase 3. Management noted that modified dose ramp-up strategies may help mitigate these effects. Despite near-term pressures, we remain encouraged by Amgen’s continued market share gains across key therapies and the potential to enhance the company’s competitiveness and resilience in a dynamic healthcare landscape.”
A pharmacist filling a prescription for a complex drug developed by the company.
mgen Inc. (NASDAQ:AMGN) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 69 hedge fund portfolios held Amgen Inc. (NASDAQ:AMGN) at the end of the first quarter, which was 72 in the previous quarter. In the first quarter, Amgen Inc. (NASDAQ:AMGN) delivered revenues of $8.1 billion, representing a 9% increase from Q1 2024. While we acknowledge the risk and potential of Amgen Inc. (NASDAQ:AMGN) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than Amgen Inc. (NASDAQ:AMGN) and that has 10,000% upside potential, check out our report about this cheapest AI stock.
In another article, we covered Amgen Inc. (NASDAQ:AMGN) and shared the list of best low volatility stocks to buy according to analysts. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None. This article is originally published at Insider Monkey.
